Abstract:Congenital heart disease (CHD) is the most common type of developmental abnormality in humans, and is a leading cause for substantially increased morbidity and mortality in affected individuals. Increasing studies demonstrates a pivotal role of genetic defects in the pathogenesis of CHD, and presently mutations in more than 60 genes have been associated with CHD. Nevertheless, CHD is of pronounced genetic heterogeneity, and the genetic basis underpinning CHD in a large proportion of patients remains unclear. In the present study, the whole coding exons and splicing donors/acceptors of the MEF2C gene, which codes for a transcription factor essential for normal cardiovascular development, were sequenced in 200 unrelated patients affected with CHD, and a novel heterozygous missense mutation, p.L38P, was identified in an index patient with patent ductus arteriosus (PDA) and ventricular septal defect (VSD). Genetic scan of the mutation carrier's family members available showed that the mutation was present in all affected family members but absent in unaffected family members. Analysis of the proband's pedigree revealed that the mutation co-segregated with PDA, which was transmitted as an autosomal dominant trait with complete penetrance. The mutation changed the amino acid that was completely conserved evolutionarily, and did not exist in 300 unrelated, ethnically-matched healthy individuals used as controls. Functional deciphers by using a dual-luciferase reporter assay system unveiled that the mutant MEF2C protein had a significantly reduced transcriptional activity. Furthermore, the mutation significantly diminished the synergistic activation between MEF2C and GATA4, another cardiac core transcription factor that has been causally linked to CHD. In conclusion, this is the first report on the association of a MEF2C loss-of-function mutation with an increased vulnerability to CHD in humans, which provides novel insight into the molecular mechanisms underlying CHD, implying potential implications for early diagnosis and timely prophylaxis of CHD.

PITX2c Loss-of-function Mutations Responsible for Congenital Atrial Septal Defects.

Novel PITX2c Loss-of-function Mutations Associated with Complex Congenital Heart Disease.

Prevalence and Spectrum of PITX2c Mutations Associated with Congenital Heart Disease.

PITX2 Loss-of-Function Mutation Contributes to Congenital Endocardial Cushion Defect and Axenfeld-Rieger Syndrome.

PITX2 Loss-of-function Mutation Contributes to Tetralogy of Fallot

PITX2C Loss-of-function Mutations Responsible for Idiopathic Atrial Fibrillation

A Novel Pitx2c Loss-Of-Function Mutation Underlies Lone Atrial Fibrillation

[Mutation of NKX2-5 Gene in Patients with Atrial Septal Defect].

A New TBX5 Loss-of-Function Mutation Contributes to Congenital Heart Defect and Atrioventricular Block

A Novel TBX1 Loss-of-Function Mutation Associated with Congenital Heart Disease.

A Novel NKX2-5 Mutation in Familial Ventricular Septal Defect.

A Novel Nkx2.6 Mutation Associated with Congenital Ventricular Septal Defect

Novel NKX2-5 Mutations Identified in Patients with Congenital Ventricular Septal Defects

MEF2C Loss-of-function Mutation Contributes to Congenital Heart Defects.

A Novel Gata4 Mutation Responsible for Congenital Ventricular Septal Defects

Prevalence and Spectrum of Nkx2.6 Mutations in Patients with Congenital Heart Disease.

Novel GATA6 Mutations Associated with Congenital Ventricular Septal Defect or Tetralogy of Fallot.

Novel NKX2-5 Mutations in Patients With Familial Atrial Septal Defects

A New ISL1 Loss-of-Function Mutation Predisposes to Congenital Double Outlet Right Ventricle.

A HAND2 Loss-of-Function Mutation Causes Familial Ventricular Septal Defect and Pulmonary Stenosis

A Novel NR2F2 Loss-of-function Mutation Predisposes to Congenital Heart Defect.